Wellington Management Group LLP Has $1.86 Million Position in ADMA Biologics Inc $ADMA

Wellington Management Group LLP cut its position in ADMA Biologics Inc (NASDAQ:ADMA) by 11.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 93,821 shares of the biotechnology company’s stock after selling 11,638 shares during the quarter. Wellington Management Group LLP’s holdings in ADMA Biologics were worth $1,861,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ADMA. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of ADMA Biologics in the 1st quarter valued at approximately $35,000. Tsfg LLC acquired a new position in shares of ADMA Biologics in the 1st quarter valued at approximately $51,000. Brooklyn Investment Group raised its position in shares of ADMA Biologics by 28,655.6% in the 1st quarter. Brooklyn Investment Group now owns 2,588 shares of the biotechnology company’s stock valued at $51,000 after buying an additional 2,579 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new position in shares of ADMA Biologics in the 1st quarter valued at approximately $52,000. Finally, Farther Finance Advisors LLC raised its position in shares of ADMA Biologics by 1,149.1% in the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 2,505 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 20,000 shares of ADMA Biologics stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total transaction of $419,200.00. Following the sale, the director directly owned 94,830 shares of the company’s stock, valued at approximately $1,987,636.80. The trade was a 17.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jerrold B. Grossman sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $21.31, for a total transaction of $213,100.00. Following the sale, the director directly owned 478,194 shares in the company, valued at $10,190,314.14. The trade was a 2.05% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 455,621 shares of company stock valued at $9,461,633. 3.50% of the stock is owned by insiders.

ADMA Biologics Trading Down 0.7%

Shares of ADMA Biologics stock opened at $17.26 on Friday. The firm has a market capitalization of $4.12 billion, a PE ratio of 20.07 and a beta of 0.38. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The firm’s 50 day moving average is $17.76 and its 200 day moving average is $18.91. ADMA Biologics Inc has a 1 year low of $13.50 and a 1 year high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.01. The company had revenue of $121.98 million for the quarter, compared to analyst estimates of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm’s revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.13 EPS. Equities research analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on ADMA shares. Wall Street Zen cut shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday, May 9th. Raymond James Financial boosted their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to data from MarketBeat.com, ADMA Biologics has a consensus rating of “Buy” and a consensus price target of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.